Company intelligence / Profile preview
Serodus
Oslo, Norwayserodus.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The lead program SER150 has completed a phase 2 study in patients with diabetic kidney disease. The company has received approval for the next SER150 clinical study from New Zealand authorities in addition to ongoing approval in Australia. Patients have been randomized in Australia.
- Therapeutic areas
- OphthalmologyEndocrinologyNephrology
- Modalities
- PeptidesAnti-inflammatory compounds
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Serodus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serodus.